|
|
Article: CSL Biotherapies Announces First Shipments of Afluria(R) Thimerosal-Free Influenza Vaccine for the 2008-2009 Flu Season.
- Article from:
- Business Wire
- Article date:
- September 4, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Newest U.S. manufacturer on track to deliver more than six million Afluria doses
KING OF PRUSSIA, Pa. -- CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of influenza vaccine, announced today that it has begun shipment of its influenza virus vaccine in the U.S. for the 2008-2009 season. CSL plans to deliver more than six million doses of Afluria and the majority of the supply will be in single-dose, thimerosal-free, pre-filled syringes.
Afluria is indicated for the active immunization of persons age 18 years and older against influenza disease (commonly referred to as the "flu") caused by influenza virus subtypes A and type B ...